Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2023. Q4 2023 and Full Year 2023 Highlights:   Q4 2023 FY 2023 Revenues   $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share   $0.41 $(0.50) Non-GAAP diluted EPS   $1.00 $2.56 Cash flow generated from operating activities   $1,184 million $1,368 million Free cash flow   $1,486 million $2,387 million Mr. Richard Francis.

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Pharmaceutical Industries will divest its active pharmaceutical ingredient (API) unit to focus on its core business, the world's largest generic drugs maker said on Wednesday.

Teva to divest active pharmaceutical ingredient business

TEL AVIV, Israel--(BUSINESS WIRE)--Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or "TAPI". TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide. The intent to divest “TAPI” will allow Teva to maximize current and potential revenue streams, focusing on capital reallocation towards growth and innovation, and to better serve patients. The intended divestiture is expected to create additional va.

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy

Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics

Merck

Sanofi

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

MONTPELLIER, France--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase 3 clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference. Results of the study are expected in the second half of 2024.1 mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophreni.

MedinCell's partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)

Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript)

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free p.

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024

Small cap and mid cap biotech and speculative pharma stocks have a more constructive outlook heading into 2024, relative to previous years, but the idiosyncratic nature of the space continues to put a premium on stock picking, according to Bank of America analysts.   In an update to clients, the analysts noted that they remain encouraged by sector fundamentals, including research and development (R&D) output and external demand for biotech innovation as measured by merger and acquisition (M&A) trends.

Small mid cap biotech, pharma stocks set for better 2024: analysts

Corcept Therapeutics

Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent infringement lawsuit filed against Teva Pharmaceuticals. A US District Court said Teva does not infringe any asserted claims of Corcept's US Patents 10,195,214 and 10,842,800, both of which concern methods of safely administering its flagship Korlym drug with drugs that are strong inhibitors of CYP3A4, an enzyme mainly found in the liver and the intestine.

Corcept Therapeutics shares sink after losing patent infringement lawsuit against Teva

Corcept Therapeutics Inc. shares CORT, -1.22% dropped 32% premarket on Tuesday after a federal court in New Jersey on Friday ruled against the drugmaker in its patent infringement lawsuit against Teva Pharmaceutical Industries Ltd. TEVA, -0.29%.

Corcept stock drops after drugmaker loses patent lawsuit against Teva

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the.

Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Indivior PLC

Indivior PLC (LSE:INDV), a company specialising in addiction treatment, has settled a legal dispute with Actavis, a part of Teva Pharmaceuticals. The disagreement was about Actavis's plan to make a generic version of a drug combining buprenorphine and a naloxone sublingual film.

Indivior settles patent wrangle with Teva subsidiary

Lovesac Company

Pinterest

SSR Mining

Wall Street has had a banner year, with the "Magnificent Seven" stocks leading the charge. Despite a handful of money-based metrics and predictive indicators pointing to a recession in 2024, my portfolio is geared toward long-term upside.

My 5 Largest Portfolio Holdings for 2024

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma. BD9 is a dual specific antibody that can block both TSLP (Thymic stroma.

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

I am upgrading Teva Pharmaceutical to "Buy" for 2024, buoyed by opioid litigation resolution and promising drugs like TEV'574. Strong Q3 2023 performance, marked by revenue growth in Austedo, Ajovy, and Uzedy, and increased R&D investment. TEV'574, in collaboration with Sanofi, shows significant promise in inflammatory bowel disease treatment, enhancing TEVA's pipeline.

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces that a post hoc analysis4 of two phase 3 clinical studies presented today at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® (fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity. Migraine and obesity are both associated with high levels of disability3 and both conditions are more prevalent amongst fem.

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 8:20 AM ET Company Participants Richard Francis - President and Chief Executive Officer Eric Hughes - Executive Vice President, Global R&D and Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Excellent. Well listen, thank you guys for joining us.

Teva Pharmaceutical Industries Limited (TEVA) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)

Generic and specialty pharmaceutical company Teva Pharmaceutical Industries Ltd. NYSE: TEVA stock has underperformed for nearly a decade.

Teva Pharma is the way to play the re-rise of generic drugs

Teva Pharmaceutical Industries (NASDAQ:TEVA) Ltd is uniquely positioned to undergo a significant transition to a more brand focused company that should drive outperformance of its stock price, according to UBS analysts.   In an update to clients, they upgraded Teva stock to ‘Buy' from ‘Neutral', while raising its price target by 37% to $13 per share, believing the stock is not pricing in the company's brand transition.

Teva Pharmaceutical analysts boost target price as brand transition underway

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 2.

Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference

Teva is an Israeli pharmaceutical company and the largest global generic manufacturer which suffered numerous challenges in recent years. The new management has a clear vision of how to deliver value to shareholders with the help of the company's strong assets portfolio. The company's fair value is estimated by me to be close to $15 billion, indicating almost 50% upside potential.

Teva: Deeply Undervalued FCF Machine

PARSIPPANY, N.J. & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States. Market availability of the product in the U.S. is expected in the coming weeks. Teriparatide injection is indicated to treat osteoporosis among certain women and men. Please see the below “What is?” section for more information. “We are thrilled to recei.

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Royalty Pharma

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): In a joint press release announcing the financing agreement: Richard Francis, President and CEO of Teva said: “Since launching Teva's Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to both continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses. We are excited to collaborate with Royalty Pharma, a major funder of innovation wi.

News for Teva Pharmaceutical Stock (TEVA)